Guizhou Sinorda Pharmaceutical Co., Ltd.

Sinorda established in 2010 and is a biomedical innovation company in the commercialization stage. The company focuses on the research and development and industrialization of innovative drugs for digestive tract diseases, tumor immunity and autoimmune diseases. It has a bioinnovative drug technology platform, a clinical medical R & D platform and an experienced international R & D team, with successful experience in innovative drug applications in China, Europe, America and other countries.

Linaprazan glureta(X842), the compan's self-developed class 1.1 new drug for thtreatment of gastric acid-related diseases, has been successfully approved for commercialization and industrialization. The sentinel lymph node T cell project for solid tumor treatment has clinical IIT research results for various tumors. In addition, the company has a number of early-stage product pipelines, including bispecific antibodies for the treatment of autoimmune disease IBD.

The company has developed rapidly through extensive cooperation with domestic and foreign pharmaceutical companies and R & D institutions, and is committed to becoming the most valuable innovative pharmaceutical enterprise in China.

+ Item

Accumulatively obtained domestic and foreign patents

Billion USD

Global acid-related disease drugs market size

142.3

Billion USD

Global autoimmune disease drugs market size

235

Billion USD

Global oncology drug market size

Committed to becoming a leader in innovative therapies for digestive tract diseases and tumors

History